Skip to content
MarketScale
‹ Back to IndustriesSciences

Researchers: Viruses Like COVID-19 Can Be Prevented With the Development of a Targeted Nasal Spray Solution

As the world continues to grapple with the ongoing COVID-19 pandemic, scientists are not just working on vaccines and treatments but also on preventive measures that could be simpler yet effective. Imagine a world where a spritz of a nasal spray could help you fight the virus? That notion isn’t just wishful thinking;…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Radwa Ewaisha · Alexandria UniversityCovid-19Dr. Radwa Emad EwaishaFaculty of Pharmacy
Share

Key takeaways

01

As the world continues to grapple with the ongoing COVID-19 pandemic, scientists are not just working on vaccines and treatments but also on preventive measures that could be simpler yet effective.

02

Imagine a world where a spritz of a nasal spray could help you fight the virus?

03

That notion isn’t just wishful thinking;…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

As the world continues to grapple with the ongoing COVID-19 pandemic, scientists are not just working on vaccines and treatments but also on preventive measures that could be simpler yet effective. Imagine a world where a spritz of a nasal spray could help you fight the virus? That notion isn’t just wishful thinking; it’s grounded in intensive research into the anatomy of our respiratory system. Scientists have identified the ports of entry that SARS-CoV-2 exploits to initiate an infection. Once these entry points are known, it becomes possible to develop targeted interventions, specifically targeting the nose. Such a preventive measure could be revolutionary. And not only in combating COVID-19, but also in preparing us for future pandemics of respiratory viruses. 

Detailing more on this exciting frontier is Dr. Radwa Emad Ewaisha, Assistant Professor of Microbiology and Immunology at the Faculty of Pharmacy at Alexandria University

She has been teaching and conducting research there since January 2019. She earned her Ph.D. in Cellular and Molecular Biology from Arizona State University. Additionally, she also obtained a Master’s there in the same field. Dr. Ewaisha also completed a Clinical Chemistry Post-PhD Fellowship at the prestigious Mayo Clinic School of Medicine. Prior to her doctorate, she earned a Master’s degree in Pharmaceutical Sciences focusing on Pharmaceutical Microbiology from Alexandria University.

Upon conclusion of recent research exploring nose cells, she added that the development of a nasal solution as a shield against viral infections could be a preventative measure for other possible viral infections. Dr. Ewaisha also stated that this nasal cell research will be groundbreaking for the pharmaceutical industry. 

Dr. Ewaisha’s Thoughts on a Nasal Spray Solution

“These researchers studied cells that line the nose and airway, and they studied the microstructures that are found on these cells, such as cilia and microvilli. They were then able to identify the specific ports of entry in our noses that SARS-CoV-2 uses to start an infection. This means that, in theory, a prophylactic nasal spray can be developed, especially one that can be used following a suspected exposure to the virus, and this has very important implications not only for COVID, but potentially for future pandemics as well. 

“This study has identified targets in these cells that, when inhibited, this can actually prevent respiratory viruses from establishing a stronghold in our nose or throat and spreading the infection to neighboring cells. These targets provide new avenues for pharmaceutical companies to develop and market a prophylactic nasal spray that can abort the infection.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Radwa Ewaisha
Radwa EwaishaAssistant Professor of Microbiology and Immunology

Scientist, Pharmacist, YouTuber, Podcaster, Assistant Professor of Microbiology and Immunology who loves to communicate science in different languages.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Radwa Ewaisha
Radwa Ewaisha

Assistant Professor of Microbiology and Immunology

Scientist, Pharmacist, YouTuber, Podcaster, Assistant Professor of Microbiology and Immunology who loves to communicate science in different languages.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512